Clinical Report: Emerging Trends in Hormone-Sensitive Cancers Among Women

Overview

This report analyzes the rising global burden of hormone-sensitive cancers (HSCs) among women, highlighting significant age and regional disparities. The findings indicate an increasing incidence in younger women, particularly in lower socio-demographic index regions, while mortality rates show a decline across all age groups.

Background

Hormone-sensitive cancers, including breast, ovarian, and uterine cancers, significantly impact women's health globally. The increasing incidence rates, particularly among younger women, necessitate urgent attention to prevention and treatment strategies. Understanding the trends and disparities in HSCs is crucial for developing effective healthcare interventions.

Data Highlights

Key Findings

• The reproductive age group showed the fastest increase in age-standardized incidence rates (ASIR) for HSCs.
• Breast cancer was the dominant subtype of HSCs in 2021, with significantly higher ASIR in older age groups.
• Dietary risks, alcohol use, and tobacco were leading contributors to breast cancer burden.
• Higher socio-demographic index (SDI) correlated with increased ASIR, while ASDR and ASDiR initially rose then declined with increasing SDI.
• Projections indicate that trends in HSC burden will continue to rise through 2035, particularly in lower SDI regions.

Clinical Implications

Healthcare professionals should prioritize screening and prevention strategies for hormone-sensitive cancers, particularly in younger women and those in lower SDI regions. Understanding the contributing risk factors can guide targeted interventions to reduce the burden of these cancers.

Conclusion

The increasing burden of hormone-sensitive cancers among women underscores the need for enhanced healthcare strategies and interventions. Addressing the disparities in incidence and mortality is essential for improving outcomes in affected populations.

References

1. American Journal of Epidemiology, 2023 -- Incidence Patterns of Endometrial Cancer in the U.S. by Race/Ethnicity and Age at Diagnosis from 2000 to 2019
2. The ASCO Post, 2025 -- Cancer Deaths Expected to Rise to Over 18 Million in 2050
3. The ASCO Post, 2025 -- AACR 2025: Trends in Breast Cancer Incidence for Women Between the Ages of 20 and 49
4. PRESS RELEASE No. 361, 2025 -- Global Burden of Women's Hormone-Sensitive Cancers
5. The ASCO Post — Accrual of Older Patients to Breast Cancer Trials: A Critical Need
6. IARC 2025 Update on Women's Hormone-Sensitive Cancers
7. ASCO Provides Guidance on CDK4/6 Inhibitors for Early Breast Cancer | MDedge
8. ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025 - ScienceDirect